MAYLIN WONG GUERRA

Results-driven scientist with a PhD in neuroscience and over a decade of experience in molecular biology, neuroscience, and pharmacological research. Specializes in discovering and developing cutting-edge therapeutic candidates across synthetic, biotechnological, and natural products. Demonstrates a deep understanding of neurological disorders and pharmacology, excels in leading multidisciplinary R&D projects, securing impactful publications and grants, drafting invention patents, and formulating protocols. Proven track record in establishing and optimizing laboratory settings to drive research efforts, ensure regulatory compliance, and foster innovation. Proficient in advanced laboratory techniques, in vitro/in vivo models of neurodegenerative diseases, data analysis and experimental design, and advanced laboratory techniques. Strong focus on team collaboration and achieving results, adapting to changing needs and delivering impactful solutions.

Wong-Guerra M, (...) Maccioni Ricardo B, Rojo-Castillo Leonel E. "Therapeutic Modulation of Neuroinflammation and Tau Pathology by the Enriched Fraction F15 from Andean Shilajit: A Novel Approach for Alzheimer’s Disease Management". Intellectual Property Process and Review 2025.

Wong-Guerra M, et al. Mitochondrial protective properties exerted by JM-20 in a dementia model induced by intracerebroventricular administration of streptozotocin in mice. Behav Brain Res. 2025 Mar 5; 480:115385

Wong-Guerra M, et al. JM-20 improves age-related cognitive impairment in mice. Neurochem Res. 2024 Nov 15;50(1):8.

Wong-Guerra M, Calfio C, Maccioni RB, Rojo LE. Revisiting neuroinflammation in Alzheimer’s: druggability of current targets. Front Pharmacol. 2023 Jun 9;14:1161850.

Andrade V, Wong-Guerra M, (...) Maccioni RB. Andean Shilajit as a neuroprotective agent for Alzheimer’s. Pharmaceuticals. 2023 4;16(7):960.

Patent PCT1/CU2017/050002: WO/2017/190713 “Benzodiazepine Derivative with Activity on the Central Nervous and Vascular Systems.”